Yanan Zhu
Stock Analyst at Wells Fargo
(1.92)
# 1,852
Out of 4,479 analysts
40
Total ratings
31.03%
Success rate
-3.99%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Overweight | $35 → $40 | $24.55 | +62.93% | 2 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $70 → $65 | $53.95 | +20.48% | 1 | May 9, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $85 → $82 | $47.11 | +74.06% | 1 | May 8, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $30 | $9.05 | +231.49% | 1 | Apr 22, 2024 | |
| AFMD Affimed | Maintains: Overweight | $30 → $25 | $5.41 | +362.11% | 2 | Apr 1, 2024 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $4 → $3 | $0.98 | +207.60% | 4 | Mar 27, 2024 | |
| MGX Metagenomi | Initiates: Overweight | $25 | $4.42 | +465.61% | 1 | Mar 5, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $22 → $25 | $8.06 | +210.17% | 4 | Mar 1, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $50 | $41.28 | +21.12% | 3 | Jan 3, 2024 | |
| VYGR Voyager Therapeutics | Upgrades: Overweight | $9 → $14 | $7.86 | +78.12% | 1 | Jan 2, 2024 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $6 → $5 | $3.26 | +53.37% | 2 | Nov 9, 2023 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $5 → $4 | $0.33 | +1,112.12% | 3 | Aug 10, 2023 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $45 | $0.65 | +6,812.44% | 1 | Mar 27, 2023 | |
| AUTL Autolus Therapeutics | Assumes: Overweight | $8 | $3.47 | +130.55% | 1 | Mar 27, 2023 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $125 → $105 | $23.05 | +355.53% | 2 | Mar 1, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $14 → $10 | $2.26 | +342.48% | 2 | Jan 4, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $55 → $48 | $2.88 | +1,566.67% | 2 | Jan 4, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $135 → $120 | $22.47 | +434.05% | 1 | Jan 4, 2023 | |
| EDIT Editas Medicine | Maintains: Overweight | $50 → $36 | $4.61 | +680.91% | 3 | Jan 4, 2023 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $3 | $1.05 | +185.71% | 1 | Nov 14, 2022 | |
| QURE uniQure | Maintains: Equal-Weight | $34 → $24 | $4.45 | +439.93% | 1 | Aug 9, 2022 | |
| ARGX argenx SE | Maintains: Equal-Weight | n/a | $434.22 | - | 1 | Feb 2, 2021 |
Spyre Therapeutics
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $24.55
Upside: +62.93%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $53.95
Upside: +20.48%
Ionis Pharmaceuticals
May 8, 2024
Maintains: Overweight
Price Target: $85 → $82
Current: $47.11
Upside: +74.06%
enGene Holdings
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $9.05
Upside: +231.49%
Affimed
Apr 1, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $5.41
Upside: +362.11%
bluebird bio
Mar 27, 2024
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.98
Upside: +207.60%
Metagenomi
Mar 5, 2024
Initiates: Overweight
Price Target: $25
Current: $4.42
Upside: +465.61%
Iovance Biotherapeutics
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $8.06
Upside: +210.17%
Avidity Biosciences
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $41.28
Upside: +21.12%
Voyager Therapeutics
Jan 2, 2024
Upgrades: Overweight
Price Target: $9 → $14
Current: $7.86
Upside: +78.12%
Fate Therapeutics
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $3.26
Upside: +53.37%
Sangamo Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.33
Upside: +1,112.12%
Alaunos Therapeutics
Mar 27, 2023
Assumes: Overweight
Price Target: $45
Current: $0.65
Upside: +6,812.44%
Autolus Therapeutics
Mar 27, 2023
Assumes: Overweight
Price Target: $8
Current: $3.47
Upside: +130.55%
Beam Therapeutics
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $23.05
Upside: +355.53%
Taysha Gene Therapies
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.26
Upside: +342.48%
RAPT Therapeutics
Jan 4, 2023
Maintains: Overweight
Price Target: $55 → $48
Current: $2.88
Upside: +1,566.67%
Intellia Therapeutics
Jan 4, 2023
Maintains: Overweight
Price Target: $135 → $120
Current: $22.47
Upside: +434.05%
Editas Medicine
Jan 4, 2023
Maintains: Overweight
Price Target: $50 → $36
Current: $4.61
Upside: +680.91%
Adaptimmune Therapeutics
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $1.5 → $3
Current: $1.05
Upside: +185.71%
uniQure
Aug 9, 2022
Maintains: Equal-Weight
Price Target: $34 → $24
Current: $4.45
Upside: +439.93%
argenx SE
Feb 2, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $434.22
Upside: -